The growth trajectory for Indian pharmaceutical industry is likely to be moderate, according to credit rating agency ICRA. Owing to slow growth from US given the relatively moderate proportion of large size drugs going off patent, increased competition leading to price erosion in low-to-mid-teens, generic ...
Read more: Indian pharma growth likely to be moderate: ICRA